Search Results - "Kupcova, Viera"

Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD by Kupčová, Viera, Fedelešová, Michaela, Bulas, Jozef, Kozmonová, Petra, Turecký, Ladislav

“…Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. It represents a range of disorders, including simple steatosis,…”
Get full text

The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec by Haahr, Hanne, Cieslarová, Blanka, Hingst, Janne R., Jiang, Shan, Kristensen, Niels R., Kupčová, Viera, Nørgreen, Lea, Wagner, Frank-Dietrich H., Ignatenko, Stanislav

“…Background and Objective Icodec is a once-weekly insulin being developed to provide basal insulin coverage in diabetes mellitus. This study evaluated the…”
Get full text

Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics by Skladaný, Lubomír, Oltman, Marian, Fraňková, Soňa, Dražilová, Sylvia, Husa, Petr, Šperl, Jan, Hejda, Václav, Urbánek, Petr, Adamcová-Selčanová, Svetlana, Janičko, Martin, Kristian, Pavol, Kupčová, Viera, Rác, Marek, Schréter, Ivan, Virág, Ladislav, Liptáková, Adriana, Ondrášová, Miriam, Jarčuška, Peter

“…Objectives The MOSAIC study gathered data on chronic hepatitis C virus (HCV) infection and its treatment in various countries worldwide. Here we summarise…”
Get full text

Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron by Dickinson, James, Lewand, Michaelene, Sawamoto, Taiji, Krauwinkel, Walter, Schaddelee, Marloes, Keirns, James, Kerbusch, Virginie, Moy, Selina, Meijer, John, Kowalski, Donna, Morton, Richard, Lasseter, Kenneth, Riff, Dennis, Kupčová, Viera, van Gelderen, Marcel

“…Background and Objectives Mirabegron, a selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), is eliminated by renal and metabolic…”
Get full text

Questionnaire for risk factors of alcoholic and nonalcoholic fatty liver disease by Szantova, Maria, Skladany, Lubomir, Janicko, Martin, Oltman, Marian, Drazilova, Sylvia, Belovicova, Maria, Zima, Martin, Kupcova, Viera, Adamcova-Selcanova, Svetlana, Koller, Tomas, Rac, Marek, Jakabovicova, Martina, Hlavata, Tereza, Faktorova, Xenia, Durkovicova, Zuzana, Szamosova, Monika, Jarcuska, Peter, Mojto, Viliam, Vorlickova, Maria

“…OBJECTIVESNon-communicable diseases are estimated to account for 90 % of total deaths and 19 % of premature deaths in Slovakia. Major preventable risk factors…”
Get full text

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis by Gane, Edward J., Rouzier, Régine, Hassanein, Tarek, Stedman, Catherine A., Mazur, Wlodzimierz, Kupcova, Viera, Le Pogam, Sophie, Eng, Simon, Voulgari, Athina, Morcos, Peter N., Brennan, Barbara J., Scalori, Astrid, Thommes, James

“…Background and aim Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. Methods An…”
Get full text

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment by Bækdal, Tine A., Thomsen, Mette, Kupčová, Viera, Hansen, Cilie W., Anderson, Thomas W.

“…Semaglutide is a human glucagon‐like peptide‐1 analog that has been co‐formulated with the absorption enhancer, sodium N‐(8‐[2‐hydroxybenzoyl] amino)…”
Get full text

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954) by Czerniak, Richard, Cieslarová, Blanka, Kupčová, Viera, Rosario, Maria, Lock, Ruth, Dong, Cheng, Dukes, George

“…Felcisetrag (formerly known as TAK‐954) is a selective serotonin receptor agonist under investigation for use in patients with postoperative gastrointestinal…”
Get full text

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment by Kupčová, Viera, Arold, Gerhard, Roepstorff, Carsten, Højbjerre, Malene, Klim, Søren, Haahr, Hanne

“…Background and Objective Insulin degludec is a basal insulin with a slow and distinct absorption mechanism resulting in an ultra-long, flat, and stable…”
Get full text

Su1502 THE ROLE OF CELL-FREE DNA IN THE PATHOGENESIS OF ACUTE AND CHRONIC LIVER DISEASE by Gromova, Barbora, Konecna, Barbora, Vašeková, Michaela, Kupcova, Viera, Celec, Peter, Gardlik, Roman

Get full text

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment by Jensen, Lene, Kupcova, Viera, Arold, Gerhard, Pettersson, Jonas, Hjerpsted, Julie B.

“…Aims To investigate whether the pharmacokinetic characteristics of semaglutide were altered in people with hepatic impairment, assessed using Child–Pugh…”
Get full text

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients by van der Ree, Meike H., van der Meer, Adriaan J., de Bruijne, Joep, Maan, Raoel, van Vliet, Andre, Welzel, Tania M., Zeuzem, Stefan, Lawitz, Eric J., Rodriguez-Torres, Maribel, Kupcova, Viera, Wiercinska-Drapalo, Alcija, Hodges, Michael R., Janssen, Harry L.A., Reesink, Hendrik W.

“…•We present the long-term safety and efficacy outcome of patients treated with anti-miR therapy.•No long-term safety issues were observed among…”
Get full text

Obesity, elevated levels of fasting plasma glucose and type 2 diabetes are associated with aortic stiffness by Kupcova, Viera, Murin, Jan, Wimmerova, Sona, Potocarova, Maria, Turecky, Ladislav, Bulas, Jozef

“…Obesity and metabolic syndrome (MetS) are associated with structural and functional vascular abnormalities. MetS and its components may increase arterial…”
Get full text

Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis – amelioration by liver transplantation by Šebeková, Katarı́na, Kupčová, Viera, Schinzel, Reinhard, Heidland, August

“…Background/Aims : Modification by advanced glycation renders macromolecules susceptible to elimination in the liver via scavenger receptors. Thus, in advanced…”
Get full text

The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A by Kupčová, Viera, Šperl, Jan, Pannier, Anne, Jordan, Paul, Dougherty, Frank C., Reigner, Bruno

“…ABSTRACT Aim: To examine the effect of severe hepatic impairment (HI) on the pharmacokinetics (PK) and pharmacodynamics (PD) of the continuous erythropoietin…”
Get full text

809-P: The Effect of Various Degrees of Hepatic Impairment on the Pharmacokinetic Characteristics of Once-Weekly Insulin Icodec by HAAHR, HANNE, CIESLAROVA, BLANKA, DONATSKY, ANDERS M., JOSEPH, JOSMIN R., KRISTENSEN, NIELS R., KUPCOVÁ, VIERA, HINGST, JANNE R.

“…Insulin icodec is a novel basal insulin being developed for once-weekly administration. This study investigated if the pharmacokinetic characteristics of…”
Get full text

Serum butyrylcholinesterase/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease by Turecký, Ladislav, Kupčová, Viera, Urfinová, Monika, Repiský, Marcel, Uhlíková, Eva

“…Cardiovascular diseases on an atherosclerotic basis are a serious health problem. Atherosclerosis is a multifactorial pathological process with complex…”
Get more information

Comparison of serum hyaluronic acid and N-acetylglucosaminidase activity in patients with chronic hepatitis by Turecky, Ladislav, Kupcova, Viera, Valkova, Martina, Szantova, Maria

Get full text

Advanced glykation end products in patients with liver cirrhosis before and after liver transplantation by Kupcova, Viera, Sebekova, Katarina, Schinzel, Reinhard, Heidland, August

Get full text

Serum hyaluronic acid as a marker of hepatic fibrosis in patients with chronic liver diseases by Kupcova, Viera, Valkova, Martina, Turecky, Ladislav, Szantova, Maria

Get full text